PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers

Several clinical trials are investigating the use of immune-targeted therapy with Programmed death ligand-1 (PD-L1) inhibitors for colorectal cancer (CRC), with promising results for patients with mismatch repair (MMR) deficiency or metastatic CRC. However, the prognostic significance of PD-L1 expre...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Pers Med
Autors principals: Siraj, Abdul K., Parvathareddy, Sandeep Kumar, Annaiyappanaidu, Padmanaban, Haqawi, Wael, Al-Rasheed, Maha, AlManea, Hadeel M., AlHussaini, Hussah F., Al-Dayel, Fouad, Al-Kuraya, Khawla S.
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7911042/
https://ncbi.nlm.nih.gov/pubmed/33530623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11020073
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars